Clinical characteristics, treatment patterns and persistence in patients with T2D initiating a Glucagon-like-peptide 1 receptor agonists (GLP-1 RA): a retrospective analysis of the Diabetes Prospective Follow-Up (DPV) registry

Background This retrospective analysis evaluates the clinical characteristics, treatment patterns and GLP-1RA persistence in patients with T2 D initiating their first GLP-1RA.

Methods Analysis of the multicentre DPV registry identified adult patients with T2 D initiating GLP-1RA therapy between 2007 and June 2020. The population was stratified by anti-diabetes therapy at time of GLP-1RA initiation into following subgroups: oral antidiabetic drugs (OAD), insulin ± OAD, or lifestyle modification (LM). GLP-1RA treatment persistence (overall and by baseline anti-diabetes treatment) in patients with ≥12-months follow-up was determined by Kaplan-Meier analysis.

Results In total, 15,111 patients with T2 D initiating a GLP-1RA therapy (55 % males) were identified. The baseline characteristics include median [interquartile range (IQR)] age (58.7 [50.6-66.7] years), diabetes duration (8.5 [3.6-14.7] years), BMI (36 [31.7-41.3] kg / m2) and HbA1c (8.2 [7.1-9.8] %). Subgroup analysis by baseline therapy (OAD:42 %, insulin ± OAD:50 %, LM:7 %) showed similar age and BMI while HbA1c varied (OAD:7.8 [6.9-9.4] %, insulin ± OAD:8.5 [7.4-10.1] %, LM:7.2 [6.4-8.4] %). The overall median [IQR] GLP-1RA persistence in eligible patients (n = 5,189) was 11 [0-51] months, with patients reaching a median HbA1c of 7.5 [6.6-8.7] % at discontinuation. Across subgroups, GLP-1RA persistence was OAD:12 [0-52] months (n = 2,453), insulin ± OAD:11 [0-54] months (n = 2,204), and LM:7 [0-36] months (n = 532), reaching a median HbA1c of 7.3 [6.4-8.5] % (OAD; n = 1,155), 7.8 [6.9-9.0] % (insulin ± OAD; n = 1,010), and 7.3 [6.4-8.2] % (LM; n = 261).

Conclusions Real-world DPV registry data revealed 92 % of patients with T2 D initiating a GLP-1RA added it to an OAD or insulin ± OAD treatment regimen, and 50 % showed a GLP-1RA persistence of > 11 months.

Interessenskonflikt

Michael Hummel receives consulting and / or honorary fees for speeches from Astra Zeneca, Berlin Chemie, Lilly, Novo, MSD, Sanofi.

Marianne Pavel: participated in a Lilly Advisory board with honorarium, and received honoraria for presentation and / or advisory boards for the following societies: IPSEN, AAA, Novartis, Riemser, Boehringer-Ingelheim.

Jeremie Lebrec serves as a consultant for Eli Lilly.

Heike Jung, Nanette Schloot, Elke Heitmann and Thorsten Otto are employees and stockholders of Eli Lilly and Company.

Michael Naudorf, Stefanie Lanzinger and Sascha Tittel have no conflicts of interest.

Publikationsverlauf

Artikel online veröffentlicht:
06. Mai 2021